The stock of Dendreon, maker of the prostate-cancer drug Provenge, fell the most in nine months after the Seattle company fell short of analysts’ revenue estimates.
Dendreon dropped 71 cents, or 15 percent, to $4.03 Thursday, its biggest decline since July 31. The stock has fallen 55 percent in the past 12 months.
First-quarter revenue fell 18 percent to $67.6 million, the company reported. Analysts expected sales of $79.7 million, the average of 19 estimates in a Bloomberg survey.
Provenge, Dendreon’s only product, began facing competition from Johnson & Johnson’s Zytiga in December.
- Husky guide on UW cheerleading tryouts goes global
- CEO makes fiery emails about Muslims part of the workday
- Look like this, not that: UW pulls cheerleader-tryout advice after angry backlash
- Oh smack: Garbage truck hits Alaskan Way Viaduct
- Seahawks’ selection of Germain Ifedi in NFL draft has makings of a great fit
Most Read Stories
“I am not satisfied with these results,” Dendreon CEO John Johnson said on a conference call with analysts and investors.
Second-quarter sales will grow to the “mid-70s range,” and the fourth quarter will be Dendreon’s strongest, he said.
Dendreon said its net loss for the first quarter narrowed to $72 million, or 48 cents a share, from $103.9 million, or 70 cents, a year earlier.
Provenge was approved in April 2010 as the first therapy in the U.S. that trains the body’s immune system to attack cancer cells as if they were a virus.
The treatment, which costs $93,000, was cleared for patients with advanced cases of the disease after the company’s three-year effort to persuade the Food and Drug Administration to back the medicine.
The first television commercial for Provenge ran March 7 as part of a direct-to-consumer advertising campaign.
Dendreon said it plans to spend $5 million each quarter on the effort.